Information Provided By: 
Fly News Breaks for March 18, 2019
STML
Mar 18, 2019 | 17:02 EDT
Piper Jaffray analyst Joseph Catanzaro kept his Overweight rating and $23 price target on Stemline, saying his conversations with the management after the company's Q4 results reflected "very positive" feedback from physicians with patient enrollments "in all major sales territories." The analyst believes that the company's Elzonris sales may reach $1.9M, and "expansion opportunities in subsets of CMML and MF" could take shape by mid-2019.
News For STML From the Last 2 Days
There are no results for your query STML
